Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationTransplantation ConditioningGraft vs Host DiseaseTransplantation, AutologousMyeloablative AgonistsHematopoietic Stem CellsPeripheral Blood Stem Cell TransplantationHematologic NeoplasmsStem CellsBone Marrow TransplantationTransplantation ChimeraTissue DonorsBusulfanTreatment OutcomeCord Blood Stem Cell TransplantationWhole-Body IrradiationGraft SurvivalHistocompatibility TestingGraft vs Leukemia EffectRecurrenceRemission InductionVidarabineLiver TransplantationRetrospective StudiesCombined Modality TherapyLeukemiaHistocompatibilityMultiple MyelomaGraft vs Tumor EffectImmunosuppressive AgentsHematopoietic Stem Cell MobilizationMelphalanLeukemia, Myeloid, AcuteSiblingsMesenchymal Stem Cell TransplantationDisease-Free SurvivalChimerismSurvival AnalysisAntigens, CD34Hepatic Veno-Occlusive DiseaseMyelodysplastic SyndromesSurvival RateLymphocyte TransfusionCell TransplantationSalvage TherapyCyclophosphamideEmbryonic Stem CellsAntilymphocyte SerumKidney TransplantationTime FactorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphocyte DepletionCytomegalovirus InfectionsHematologic DiseasesHematopoiesisPrecursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Combined Chemotherapy ProtocolsHLA AntigensAdult Stem CellsCell DifferentiationTransplantation ImmunologyUnrelated DonorsMinor Histocompatibility AntigensNeoplasm, ResidualBone Marrow CellsFollow-Up StudiesAcute DiseaseGranulocyte Colony-Stimulating FactorT-LymphocytesStem Cell NicheLymphoma, Non-HodgkinTransplantation, IsogeneicAnemia, AplasticVirus ActivationGraft RejectionPrognosisFlow CytometryCytarabinePluripotent Stem CellsHeart TransplantationBone MarrowImmunosuppressionCell LineageCytomegalovirusLeukemia, MyeloidMesenchymal Stromal CellsHodgkin DiseaseInfectionImmunocompromised HostLung TransplantationLymphoproliferative DisordersMice, Inbred C57BLOpportunistic InfectionsEtoposideNeural Stem CellsAntineoplastic AgentsLiving DonorsOrgan Transplantation